BIOTECH ASSISTANT / FIELD NOTES

Nurix previews updated bexobrutideg Phase 1 CLL/SLL findings for ASH

Company / institutional announcement · Nurix Therapeutics

Source published: 2026-11-05 · Event / reporting date: 2026-11-05

Site published: 2026-11-06 · Updated: 2026-11-06

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.

Why it may matter

Analysis: Updated dose-specific evidence may help developers assess the clinical differentiation of BTK degradation after covalent inhibitor treatment.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Protein degradation / PROTAC

Related updates

2026-11-05Amphista Therapeutics / Business Wire

Amphista previews BRD9 degradation findings and BRAMLIE trial design at ASH

Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.

Protein degradation / PROTAC Ask AI ↗

2026-11-04Proceedings of the National Academy of Sciences / PubMed

Bispecific protein drives dual receptor degradation in mouse eye-disease models

A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.

Protein degradation / PROTAC Ask AI ↗

2026-11-04Arvinas

Arvinas schedules first zaloblideg Phase 1 findings for ASH

Arvinas announced an ASH poster on preliminary Phase 1 findings for oral BCL6 degrader ARV-393, also called zaloblideg, in relapsed or refractory non-Hodgkin lymphoma. The December 14 presentation will cover safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in T-cell lymphomas. The announcement itself does not provide numerical response results.

Protein degradation / PROTAC Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗